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1. Introduction  
The blood brain barrier (BBB) is one of the factors hampering the development of new 
therapies and in many cases limits the access of the therapeutic agent to the neural tissue. 
The BBB consists of a specialized vascular structure formed by the interaction between 
endothelial cells and numerous processes of astrocytes regulating the passage and diffusion 
of molecules between plasma and the central nervous system (CNS) (Pardridge, 2005). The 
endothelium is distinguished from other tissues by the presence of tight junctions between 
endothelial cells (which limit the exchange of even low molecular weight substances) and a 
reduced endocytic and pinocytic activity. Small molecules (usually less than 500 Da) and 
some lipid-soluble small peptides can pass the BBB without the mediation of specific 
transporters. However, in most cases, the transfer across the BBB requires receptor-mediated 
transcytosis or selective transporters, such as low density lipoprotein receptors (LDLR), 
insulin receptors, leptin receptors, transferrin receptors and insulin-like growth factor 
receptors (Pardridge, 2005). The number of specific transporters mediating the transfer of 
substances through the BBB is very high and probably accounts for a very substantial part of 
the more than 2,000 membrane transporters that probably function in the human cell. We 
present, in this review, some of the newly developed approaches to overcome this barrier 
and facilitate the access of therapeutic genes to the nervous system. 
Parkinson's disease (PD) is considered here as being neurological diseases for which no 
etiopathogenic treatment is available and may be susceptible to gene therapy. Different 
proteins such as human glial cell line-derived neurotrophic factor (GDNF), brain-derived 
neurotrophic factor (BDNF)...which are able to reduce the vulnerability of dopaminergic 
neurons in laboratory animals have been described in the last ten years. For various reasons, 
the central administration of these proteins has not been effective in patients (short half-life, 
poor diffusion in neural tissue ...). Since the cellular and neurochemical substrate of the 
disease, and various proteins with neuroprotective capacity for these cells are known, gene 
therapy is outlined here as a future therapeutic option. 
2. Gene therapy: An alternative treatment for neurodegenerative diseases 
Conventional drugs of low molecular weight are designed to spread in cells with precise 
kinetics and, where necessary, use specific transport systems. Protein therapy is more 
complex, especially when act intracellularly, because there are not many cellular pathways 
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to import proteins. Moreover, these molecules cannot be orally administered. The situation 
regarding the delivery of nucleic acids is complex because of their size (MDa) and the lack of 
systems to import them through the cell membrane, especially in the cell nucleus. Therefore, 
nucleic acids need to be packaged into either virus particles in a natural way to meet many 
of these conditions or artificial particles that can replace the virus. The treatment half life is 
also completely different since the transformation which is achieved with nucleic acids can 
mean a permanent alteration, unlike conventional drug treatment which is inherently 
transient. 
Gene therapy is defined as the introduction of nucleic acids into cells to alter the course of a 
medical condition or disease. Initially proposed for the treatment of monogenic diseases, 
gene therapy is now recognized as ' a new form of drug delivery ' offering various strategies 
for the treatment of inborn and acquired diseases. If the future of gene therapy is to 
successfully compete with traditional drug treatment, it will be necessary to have economic, 
simple and effective methods of gene transfer. 
The expression of exogenously administered genes in the brain has been proposed as an 
alternative therapy for a wide variety of inherited and acquired diseases of the CNS for 
which classical drug therapy is not affordable or not readily applicable. Gene transfer into 
the CNS has been investigated as a strategy to protect against neuronal damage and 
degeneration. The best candidates for gene therapy are neurotrophic factors, antioxidants- 
or antiapoptotic molecules, and different specific molecules of cell signaling, which are of 
great interest in neuroprotection in pathological conditions where, as in Parkinson's disease, 
there is free-radical production (Tenenbaum et al., 2002). 
The choice of vehicle (vector) to carry the therapeutic gene (transgene) to the desired tissue 
or cell type is crucial to achieve successful gene transfer. Basically, the vectors used in gene 
therapy can be divided into two groups, viral and nonviral, each of which has advantages 
and disadvantages. Some viral vectors which have proven to be effective in vivo gene 
transfer into the CNS (especially lentivirus and adeno-associated virus) can be integrated in 
the chromosomes of transduced cells, favoring a lasting expression of transgene in 
experimental animals (Thomas et al., 2003). In several cases, some cell lines are genetically 
transformed to produce neurotransmitters or neurotrophic factors in large quantities, called 
ex vivo gene therapy, in order to be used as therapeutic alternatives for CNS disorders. 
However, viral vectors present important problems regarding their production and safety 
(Kaiser, 2002). In addition, some viral vectors induce an immune response which reduces 
the effectiveness and biosafety with repeated dosing. A further complication of the use of 
certain viral vectors is their tendency to integrate near promoters and transcriptional units, 
thereby increasing the possibility of adverse effects (Essner et al., 2005). 
A significant effort has been made to develop non-viral alternative strategies of in vivo gene 
transfer in recent years. Naked DNA linked to a variety of molecular conjugates, such as 
liposomes, non-lipid nanoparticles, polymers and polypeptides has been used to this end. 
The manufacture of large-scale DNA is feasible and reproducible with these vectors, and the 
final product does not require sophisticated storage conditions. In addition, nonviral vectors 
have no restrictions regarding the size of the gene and do not cause a significant immune 
response (Conwell & Huang, 2005). However, with the use of a non-viral vector, the input of 
genetic material into the cell is limited due to the need to provide the DNA in the cell 
surface in sufficient concentrations for entry (Luo & Saltzman, 2000). It is also difficult for 
non-viral vectors to induce a lasting expression of therapeutic gene (Conwell & Huang, 
2005; Pathak et al., 2009). Although this limits the time for use in gene therapy of brain 
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diseases, it is also true that there has been spectacular growth, in recent years, in terms of 
diversity, properties and manufacturing. 
The choice of an appropriate vector to transfer the desired gene in the affected brain area is 
crucial to establish a safe and efficient gene therapy for CNS. In recent years there has been 
much research into gene therapy, with significant progress in developing new gene transfer 
strategies in the CNS and in evaluating their potential in treating neurological diseases. 
Among the various systems developed for this purpose, viral vectors have undoubtedly 
been used most. However, due to the impediment of gene medicines in crossing the BBB, 
most of the work undertaken used adeno-associated viral vectors or lentiviral vectors (using 
invasive routes of administration such as intracerebral injection and craniotomy) that also 
produce a localized gene expression.  
Although direct intracerebral injection of viral vectors expressing transgene-invasive gene 
therapy (iGT)-may be a reasonable alternative for localized treatment of neurodegenerative 
diseases, in which discrete brain structures are involved, the treatment of many neurological 
disorders requires the transfer of the transgene throughout the CNS. On the other hand, the 
small size of mice (major animal model) favors a more distributed gene expression, as only 
five vector injections are necessary throughout the brain. However, the larger human brain 
would require too many local injections, making the procedure clinically impractical. 
Therefore, in recent years there has been a dramatic shift in the strategies of non-invasive 
transfer of therapeutic genes in the CNS, non-invasive gene therapy (niGT) -. In this type of 
gene transfer, nucleic acids are indirectly introduced (usually via blood) in nervous tissue, in 
order to achieve therapeutic benefit, thus avoiding their direct injection into the brain 
parenchyma and damage to the BBB. The types and more important characteristics of non-
viral and viral vectors that enable the realization of a niGT in the CNS will be described 
below. 
3. Adenoassociated vectors: The most widely used in gene therapy for 
Parkinson’s disease 
The adeno-associated viruses (AAV) are small non-enveloped virus of 20-24 nm in diameter, 
which are not associated with any disease in humans (Blacklow et al., 1968). The 4.7-kb 
genome of the virus is packaged as a molecule of single- stranded DNA, it becomes double-
stranded after infection. Recombinant AAV vectors (AAVr) lack 96% of the viral genome, 
which has been removed to leave only the two inverted terminal repeats involved in 
packaging and integration (Srivastava et al., 1983). The conventional method for generating 
viral stocks is to perform a transient cotransfection of 293T cells with plasmids containing 
the vector genome, rep and cap genes and adenovirus helper (Xiao et al., 1998). There have 
been recent improvements in vector production AAVr, resulting in higher titers (between 
about 100 and 10,000 times), and a higher proportion of infectious particles as well as free 
preparations of adenovirus (Zolotukhin, 2005). AAV vectors express stably transgenic 
products in dividing- and in non-dividing cells, and although the absence of viral genes 
theoretically minimizes the risk of activating the host immune responses, this will depend 
largely on the serotype used and the target tissue (Lowenstein et al., 2007; Wang et al., 2010). 
A small cloning capacity (3-4 kb) and a delayed expression of the transgene (2-3 weeks) can 
be included among the limitations of AAV vectors (Paterna and Büeler, 2002). 
The human AAV was discovered in 1965 as a contaminant of adenovirus preparations. 
Following the description in 1982 of the first infectious clones of AAV2, this virus has been 
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rapidly gaining popularity in gene therapy applications due to features such as the lack of 
pathogenicity, wide range of infectivity, and the ability to set a long-term transgene 
expression. As more serotypes are characterized and more capsids of different serotypes are 
combined to obtain new tropisms, it is possible that tissues which are difficult to infect with 
known serotypes of AAV are capable of gene transfer. This will help to expand the current 
range of AAV vectors. AAV serotypes share a common genomic structure but show 
variation in cell and tissue tropism due to differences in their capsid proteins. This involves 
recognition of different cell surface receptors. 
So far we have identified nine serotypes of AAV vectors, and the studies with reporter genes 
have shown that these vectors efficiently infect the neurons (Cearley et al., 2008). The 
receptors responsible for the infection of AAV vectors in neurons are not fully characterized. 
The coinfusion of heparin and mannitol increases the diffusion of AAV2 vectors. In 
addition, the activity of coreceptors is necessary for a successful viral entry (Qing et al., 
1999). Previous mannitol intravenous infusion in mice not only induces a global 
transduction in the CNS, facilitating the entry of AAV2 which is also injected intravenously, 
but also produces therapeutic benefits in models of neurological diseases in which there is a 
generalized affectation (McCarty et al., 2009 ). The cells which are permissive to AAV2 
vectors express a number of factors, including the fibroblast growth factor receptor and the 
ǃ5 subunit of integrin, ǂvǃ5 (Qing et al., 1999;  Summerford et al., 1999). Compared to the 
AAV2 vector, the AAV5 serotype produces a higher- transduction and distribution in the 
brain (Davidson et al., 2000). Thus, AAV transduction in any organ is closely linked to the 
local density of a specific receptor.  
AAV infection is initiated by binding receptors that are serotype-specific to the cell surface. 
For example, heparin sulfate proteoglycan (HSPG) is one of the main AAV2 receptors 
(Summerford & Samulski, 1998). Binding to a receptor is not a sufficient stimulus for viral 
internalization, which also needs coreceptors, such as integrin heterodimers , fibroblast 
growth factor type 1 receptor and hepatocyte growth factor receptor, c-Met (Dos Santos & 
Beyer-Nardi, 2008). HSPG has a ubiquitous distribution in cells and tissues of various 
species. This partly explains the broad tropism of this virus into human, nonhuman primate, 
canine, murine and bird cells. Some derivatives of sialic acid act as AAV4 and AAV5 
receptors, while the platelet-derived growth factor receptor is another cellular determinant 
involved in AAV5 infection (Di Pasquale et al., 2003). Different AAV serotypes 
preferentially transduce different cell types. In general, tropism is associated with the 
abundance of a specific receptor /coreceptor, although there are exceptions (Duan et al., 
2000). This suggests that there are probably other internalization ways that are independent 
of known receptors (Ding et al., 2005). 
In the past decade, viral gene transfer has progressed from being merely an application in 
animal research to become an experimental therapeutic strategy in humans. From the 
clinical and therapeutic standpoint it is essential to know the distribution in tissue and 
kinetics (onset, duration and removal of the expression) of AAV vectors. To date numerous 
AAV serotypes with variable tropism have been identified. The level of homology of amino 
acids in the capsid protein of serotypes 1 to 9 is about 45% (Chiorini et al., 1999; Gao et al., 
2002), with the most divergent serotypes being AAV4 and AAV5. Many studies have 
conducted evaluations on the tropism of different AAV serotypes. Serotypes 1, 2 and 5 
(Burger et al., 2004), 7-9, and rh10 (one serotype of primates), 1, 2, 5, 7 and 8 (Taymans et al., 
2007), 2, 5, 8 and rh10 (Sondhi et al., 2007), 8, 9, and rh10 and rh43 (Klein et al., 2008) have 
been used in the brain.  
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An important limitation of previous studies was that the lack of uniformity in the design of 
plasmids, as in the production, purification and route of administration, made it difficult to 
compare the efficiencies of transduction of these serotypes in different tissues. In order to 
control the variability in these parameters, the design of plasmids, transfection, purification, 
titration, dialysis, storage and injection have been standardized for all AAV serotypes 
examined. These limitations are solved by the use of marker genes in which expression can 
be viewed at different times, via longitudinal studies in each animal. Thus, when using 
luciferase as a transgene one can evaluate the transgenic protein activity after 
intraperitoneal injection of its substrate (luciferin). This allows sequential measurements in 
the same animal (Lipshutz et al., 2001; Wu et al., 2001). Consequently, the differences in the 
efficiencies of transduction and biodistribution profiles will only reflect the differences in 
capsids of the virions of these serotypes.  
The tropism and expression kinetics for 9 different serotypes of AAV have recently been 
studied, which have been packaged, produced, purified and injected by the same systemic 
route (Zincarelli et al., 2008). This administration route is therapeutically realistic, as it 
allows the specific expression in tissues, provided that specific promoters are used along 
with the administration of vectors. In the afore mentioned study a sequential follow up of 
transgene expression for 100 days, and 9 months after the intravenous administration of 
serotypes 1-9 of AAV that expressed the luciferase transgen (controlled by an early 
promoter/activator of CMV and flanked by ITR sequences of AAV) was carried out in mice. 
The bioluminescence image revealed three expression levels: a) serotypes AAV2, 3, 4 and 5 
were in the low expression group, b) AAV1, 6 and 8 belonged to the moderate expression 
group, and c) and AAV7 and 9 corresponded to the high expression group. There was great 
variation in the kinetics of expression between these serotypes, where AAV7 and 9 induced 
a faster expression onset, and AAV3 and 4 induced a slower expression. It has been also 
shown that the primary targets for serotype 1, 2, 5, 6, 7 and 9 are liver and skeletal muscle, 
and was AAV9 whom induced greater gene expression in the heart. AAV8 and 9 induced a 
more ubiquitous transduction than other serotypes, but AAV9 generated a more robust 
expression. Within the high expression group, AAV9 also produced the largest number of 
viral genome copies in all examined tissues (especially liver, heart and skeletal muscle) 
except in the testes and lung. Significantly, the expression in the testes is an important safety 
issue for future clinical research with this serotype. 
AAV particles are currently the preferred vehicle for gene transfer in the CNS, because they 
are not pathogenic, they can transduce postmitotic cells (neurons, astrocytes and 
oligodendrocytes) (Carter & Samulski, 2000; Monahan & Samulski, 2000), persist in cells 
without causing insertional mutagenesis, allow a long-term gene expression in the brain 
(important for the treatment of chronic disease) and spinal cord (Lo et al., 1999; Wu et al., 
1998) as well as peripheral nervous system, with no associated immune response (Chen et 
al., 2007; Federici & Boulis, 2007). In addition, AAV vectors are safe, non toxic and 
incompetent for replication. The use of AAV vectors for trophic factor gene transfer to CNS 
also provides the added benefit of producing physiological levels of the protein, thereby 
avoiding side effects associated with large doses (Tenenbaum et al., 2000). Since the first 
successful application in 1984 using serotype 2 of AAVr (AAV2) as a vehicle for gene 
transfer, numerous AAVr serotypes have been isolated and characterized. Although many 
of these viruses have good transduction efficiencies in various body organs via simple 
administration, generalized transduction of CNS with relatively non-invasive methods is 
ineffective. We have commented previously that the BBB acts as a protective barrier that 
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excludes potentially harmful molecules and organisms according to their size, charge and 
lipid solubility. Consequently, the BBB effectively blocks the spread of AAVr in the CNS 
(Manfredsson et al., 2009). Researchers then had to resort to directly injecting viral vectors 
into the brain. These injections produce a robust transduction, but are relatively local and 
require invasive neurosurgery.  
There are currently AAV vectors expressing different capsid proteins with the ability to 
transduce different cell types of the CNS. Transduction varies depending on the AAV 
serotype used and the injected brain region. In the mouse brain, AAV1 and 5 can transduce 
neuronal cells and glial cells, while AAV2 can only transduce neurons (Davidson et al., 2000; 
Wang et al., 2003). AAV2 can only transduce cells of the nervous system located in the 
vicinity of the injection site. This implies the need for multiple injections or using agents 
such as mannitol or heparin to cover larger areas of the CNS (McCarty et al., 2004; Nguyen 
et al., 2001). After having examined the characteristics of transduction in the adult mouse 
brain, the following four new serotypes have recently been discovered in primates: AAV7, 8, 
9 and Rh10 (Cearley & Wolfe, 2006). Some of the AAV serotypes previously characterized , 
such as AAV1, AAV2 and AAV5, have varying levels and specificity of transduction 
(depending on the site of injection) when administered directly into the brain. For example, 
a large proportion of dopaminergic neurons in the substantia nigra are infected with an 
AAV2 vector, and the transduction efficiency and diffusion is much lower in the striatum 
(Björklund et al., 2000). 
Most information about efficiency and specificity of AAV vectors for treating CNS disorders 
comes from studies in animal models in which different vectors are evaluated according to 
their potential to ameliorate the symptoms of a disease or syndrome. The first clinical trial 
data in describing gene transfer mediated by AAV vectors in Parkinson's disease, 
Alzheimer's disease, and Canavan (an autosomal recessive degenerative disorder) are now 
being reported. 
Although invasive strategies for gene therapy are used or proposed for neurodegenerative 
diseases there are now new serotypes of AAV (as AAV9) that enable non-invasive transfer 
of transgenes in the CNS. 
4. Current gene therapy strategies for Parkinson’s disease 
Three strategies of gene therapy in parkinsonian patients were first tested in 2006, two were 
aimed at achieving direct symptomatic benefit and the other was aimed at preventing the 
natural course of the disease. In the first study, the gene transfer of aromatic amino acid 
decarboxylase (AAD, an enzyme that metabolizes levodopa to dopamine) to the striatum of 
PD patients was carried out, using AAV2 (Eberling et al., 2008). The aim was to optimize the 
symptomatic response to levodopa administration which could then be metabolized to 
dopamine more stably and constantly. However, the most convincing results were achieved 
with a triple enzyme transfer approach delivery, using the GTP cyclohydrolase 1 gene 
(GCH1) in addition to tyrosine hydroxylase (TH) and AAD genes (Shen et al., 2000; Azzouz 
et al., 2002; Muramatsu et al., 2002).   
Dietary tyrosine (Tyr) passes the blood–brain barrier and is taken up and processed by the 
dopaminergic neuron. Tyr is converted by TH into L-3, 4-dihydroxyphenylalanine (DOPA), 
which is in turn converted by the aromatic amino acid decarboxylase into dopamine. TH is 
the rate-limiting enzyme in the dopamine synthesis pathway and its activity is highly 
dependent on the presence of tetrahydrobiopterin (BH4) which acts as a cofactor. BH4 itself 
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is synthesized from GTP in a three-enzyme reaction where the activity of the GCH1 enzyme 
is rate limiting. A lentiviral vector of non-human origin was used in the triple enzyme 
transfer approach, now commercially known as Prosavin , which includes the three 
necessary genes for dopamine production and where the TH gene lacks the coding region 
for the regulatory N-terminal part of the enzyme to avoid negative feedback from cytosolic 
dopamine (Björklund et al., 2010). A clinical trial using this vector was started in 2007. One 
drawback of the two approaches that are now being used in clinical practice for enzyme 
replacement for treatment of PD patients is that the vectors used almost exclusively 
transduce the intrinsic striatal neurons, i.e., cells that do not normally produce dopamine 
(Björklund et al., 2010)). Therefore, it is conceivable that the accumulation of cytosolic 
dopamine and its end products will expose the transduced cells to excessive oxidative 
stress, since striatal transduced cells lack the vesicular storage and release mechanisms, 
possibly leading to toxic damage or neurodegeneration (Chen el al., 2008; Björklund et al. 
2010). Moreover, non-regulated dopamine production induced by overexpression of 
aromatic amino acid decarboxylase may trigger or aggravate dyskinesias (Bankiewicz et al., 
2006; Eberling et al., 2008).  
The same AAV vector for gene transfer of glutamic acid decarboxylase to the subthalamic 
nucleus was used in the second approach. The aim was both to facilitate GABAergic 
transmission in this region, thereby reducing the overactivation of subthalamus-nigral 
glutamatergic neurons that mediate a substantial part of the characteristic PD disorders (in a 
manner analogous to that induced both by lesions and deep brain stimulation in that region) 
and to normalize output from the nucleus (by adding an inhibitory GABA outflow, thereby 
reducing excessive excitatory glutamate output to key targets such as the globus pallidus 
interna and the substantia nigra reticulata). This strategy has also reached phase I clinical 
trials: the unilateral injection of AAV2-GAD into subthalamic nucleus showed that this 
procedure was safe and was associated with improvements of parkinsonism (Kaplitt et al., 
2007). Although studies of other gene, cell and biological therapies in patients with PD have 
also shown promise in small, open-label studies, subsequent randomised double-blind 
clinical trials have not substantiated their initial findings (Marks et al., 2010). A double-blind 
randomised trial was recently conducted at seven centres in the USA specialising in PD care 
and functional neurosurgery (Lewitt et al., 2011). This trial was conducted to assess the 
effect of bilateral delivery of AAV2-GAD into the subthalamic nucleus compared with 
bilateral sham surgery in patients with advanced PD. The use of this approach in this small 
phase 2 trial was intended to serve mainly as a proof-of-concept study, and the authors 
found evidence of a benefit of subthalamic nucleus AAV2-GAD surgery versus sham 
surgery. The authors also commented that several secondary outcome measures did not 
show improvement in the AAV2-GAD treatment group compared with the sham group. 
This result might indicate the absence of a benefit or relate to the fact that this small phase 2 
trial was likely to be underpowered for some of the clinical outcomes that are more difficult 
to achieve, such as, improvement in function, daily living activities and quality of life 
measures (Lewitt et al., 2011). Subsequent larger clinical trials will be needed to assess 
whether this treatment is practical for more widespread clinical use.  
The third approach uses CERE-120, an AAV2-based gene transfer vector designed to deliver 
the neurotrophic factor human neurturin (NRTN) to these degenerating neurons as a 
treatment for PD. Neurotrophic factors are naturally-ocurring proteins that restore function 
and prevent death of damaged neurons. A phase 1 trial in 12 moderately advanced PD 
patients did not identify any safety issues, while suggesting possible improvements in 
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several measures of motor function (Marks et al., 2008). A subsequent double-blind-
controlled Phase 2 trial in 58 subjects further supported the safety of CERE-120, but failed to 
discern any benefit compared to sham surgery on the primary endpoint (UPDRS-motor-
“off” at 12 months) although there were hopeful signals in the subgroup with longer follow-
up and in secondary measures (Marks et al., 2010). Two PD patients in the Phase 2 trial died 
from non-AAV2-NRTN-related events, and their brains were examined histologically. 
Although results showed NRTN-immunostaining in the targeted striatum, however, only 
scarce evidence of neurturin was seen in the substantia nigra compacta (SNc) cell bodies in 
PD (Bartus et al., 2011). These authors have proposed that human PD is associated with an 
underlying defect in axonal transport such that there is no effective delivery of NRTN from 
the source in the putamen to the dopaminergic neurons in the SNc. Their observations also  
suggest that the transport defect in PD is widespread in the brain: they not only noted 
deficient retrograde transport to the SNc, but also an absence of anterograde transport to the 
SN pars reticulata, suggesting that the disease produces defects in transport in 
dopaminergic and non-dopaminergic neurons (Bartus et al., 2011; Lewis and Standaert, 
2011). In animals, Cere-120 not only increases the endogenous synthesis of dopamine, but 
also protects dopaminergic neurons from the effects of various neurotoxic agents (Kordower 
et al., 2006), rescuing them from the degenerative process (Herzog et al., 2007). As is the case 
in any experimental therapy, caution is paramount, but balanced against the potential for a 
transformative therapeutic breakthrough, it seems right to proceed with further clinical 
studies. 
5. AAV9: The viral vector crossing blood brain barrier 
The ability of AAV type 9 (AAV9) to cross the BBB after intravenous infusion (both newborn 
and adult mice) and transduce large areas of the brain and spinal cord has recently been 
reported (Foust et al., 2009). This finding has been subsequently corroborated by a second 
independent group (Duque et al., 2009). The results obtained are of great importance, given 
the longstanding interest in developing vectors that could cross the BBB. A single 
intravenous AAV9-GFP injection to newborn mice induced a wide transduction in neurons 
throughout the CNS; For example, transduction was observed in almost 60% of motor 
neurons of the spinal cord, in about 65% of Purkinje cells, and 10-20% of neurons in the 
cortex and hippocampus. Differential exposure of a receptor on the cell surface may explain 
the propensity of the virus to transduce a larger diversity of neurons in the brain after i.v. 
injection. However, intraparenchymal injection of the vector affected neurons located in 
regions that were poorly transduced after systemic injection, for example, the striatum. 
These results have raised some questions (Saunders et al., 2009): what the role of 
hemodynamics in the circulation of the virus is and if transduced neurons are simply a 
product of a greater blood flow reaching them. 
Transduced cell types changed from neuronal to glial when AAV9-GFP was intravenously 
injected in adult animals. Thus, transduction of astrocytes and to a lesser extent of microglial 
cells was observed throughout the CNS, with nearly 60% of astrocytes in the spinal cord 
being transduced. It is interesting to note that the AAV9 mediated glial transduction was 
seen only after intravenous infusion, whereas intraparenchymal injection induced the 
classical neuronal pattern of transduction. Why does glial transduction depend on the route 
of administration? It is possible that viral receptors are only expressed in feet of astrocytes 
that line the brain blood vessels, therefore, restricting access to neurons (Abbott, 2005).  
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The AAV9 entry mechanism into cells is still to be resolved, as understanding the polarity of 
the astrocytic transduction can help determine AAV9 receptors. However, it was recently 
reported that terminal N-linked galactose is the primary receptor for AAV9 (Shen et al. 
2011). In the study by Foust et al (Foust, et al., 2009), it appears that AAV9 peripheral 
administration in adult mouse infected astrocytes, once the virus interacts with the feet of 
perivascular astrocytes which are in direct contact with vascular endothelial cells. These 
cells may contain a population of receptors different from those exposed when making 
direct injections into the brain parenchyma, and the AAV9 mediated transduction properties 
were especially interesting. Even if the BBB were opened in the adult by the use of drugs, 
one would not expect that the particles which were still AAV of 80 nm to cross the BBB, 
thereby preventing the free access to potential AAV receptors in brain parenchyma 
(Manfredsson et al., 2009). However, following intravascular delivery, AAV9 and other 
vectors crossing BBB also target liver, heart, skeletal muscle and other tissues, which may 
cause untoward effects. A major challenge is to confine transgene expression to the CNS 
when rAAV9 is delivered systemically. Historically, CNS specific promoters have been used 
 
 
Fig.1. Intravenous injection of GFP-encoding AAV9 mediates substantia nigra transduction 
in old C57BL/6J mice (twenty months old). A substantia nigra anti-GFP 
immunohistochemistry staining was carried out after 6 weeks of AAV9 i.v. injection (4x1011 
vg in 200 μl). GFP+ cells can be observed with different intensities of expression.  Scale bar 
500 μm. 
to limit transgene expression to the CNS. However, tissue-specific, strong CNS promoters 
are often too large to be packaged into the rAAV genome. Several potential challenges 
remain to using rAAV9 to treat CNS disorders. The first challenge is to deliver rAAV 
specifically to the CNS. As an alternative, tissue-specific endogenous microRNAs (miRNAs) 
were recently used to repress rAAV expression outside the CNS, by engineering perfectly 
complementary miRNA-binding sites into the rAAV9 genome (Xie et al., 2011). MicroRNAs 
(miRNAs) are a unique class of short, non-coding RNAs that mediate post-transcriptional 
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regulation of gene expression ranging from developmental processes to disease induction or 
amelioration. The authors reported the use of miRNAs to detarget rAAV9 expression both 
separately and concurrently in the liver, heart and skeletal muscle which are the three 
tissues that are most efficiently targeted by intravenously delivered rAAV9 (Zincarelli et al., 
2008; Xie et al., 2011).These are promising findings which could facilitate the development of 
miRNA-regulated rAAV for CNS-targeted gene delivery and other applications. 
AAV9 employment may have important implications for the treatment of PD (Fig.1). 
Neurotrophic factors that are secreted, such as GDNF and Neurturin, are important 
therapeutic agents which have been proposed for the treatment of PD. Since most of these 
factors are secreted by glia it is easy to imagine that overexpression of trophic factors AAV9 
mediated in these cells should produce a significant improvement in cell rescue, similar to 
or better than that found when the same neurons are therapeutic targets.  
6. Nanoparticles-based vectors crossing blood brain barrier 
Almost 70% of current clinical trials use viral vectors as vehicles for delivering DNA into 
cells to repair defective genes. Although viral vectors are effective and are widely used, it is 
also true that there are still some important safety aspects to be considered when viral 
particles are used in a therapeutic program (Thomas et al., 2003). The real goal is to achieve 
an efficient, non-invasive and non-viral gene therapy for the brain because of the obvious 
side effects of the viral vectors. This will require multidisciplinary approaches from different 
fields such as engineering, chemistry, cell biology, physiology, pharmacology and medicine. 
Although this ideal scenario has not been reached yet, a considerable amount of work on 
nanotechnological gene-delivery strategies to cross the BBB has been done. 
The last fifteen years have seen the beginning of another scientific revolution, other than 
gene therapy, based on the ability to measure, manipulate and organize matter on the 
nanometer scale. Nanotechnology is defined as the set of knowledge and methodologies to 
study, manufacture and characterize functional structures with dimensions of less than a 
few tens of nanometers. The application of nanotechnology in biomedical research is having 
a significant impact on the development of new types of diagnostic and therapeutic tools. A 
key focus is the development and use of non-viral vector-based nanoparticles to bring about 
safe and efficient gene transfer. Among the major advantages of nanoscale vehicles for 
transfer of drugs is their ability to cross membrane barriers, particularly in the CNS.  
The term "nanoparticle" refers to a structure with a diameter in the range of 1 to 100 nm, and 
was among the first nanoscale materials to have been directly used in biological systems. 
They must be functionalized in some way to be effective, which means the ability to be filled 
with, or attached to, therapeutic molecules (such as drugs, nucleic acids ...) or labeled with 
antibodies or nucleic acids to facilitate detection of a target of interest. They can be made by 
way of nanocrystals, drug-polymer complexes, or by creating nanoscale spheres (liposomes) 
able to catch molecules of drugs or other agents (LaVan et al., 2003).  
Polymeric nanoparticles have been effective in gene transfer studies (Cohen et al., 2000). 
They are colloidal particles carrying drugs or genes of interest within a biodegradable 
polymer matrix. Depending on the method of preparation, nanoparticles, nanospheres or 
nanocapsules may be obtained. Nanospheres consist of a polymer matrix in which the drug 
or gene are physically and uniformly dispersed, while nanocapsules represent vesicular 
transport systems in which the drug or gene is confined in a cavity surrounded by a matrix 
polymer. Polymeric nanoparticles are more efficient in terms of transport of drugs /genes 
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compared with traditional oral and intravenous methods (Soppimath et al., 2001). These 
advantages stem from two basic properties: 1) their small size favors penetration through 
small capillaries, allowing a greater accumulation of the drug /gene at the target site 
(Soppimath et al., 2001), this is particularly relevant in the CNS, in which the transport of 
some drugs is limited because of their inability to cross the BBB and 2) the application of 
nanoparticles as vehicles for transport of drugs / genes may help overcome this obstacle. In 
fact, it has recently been shown that polymeric nanoparticles are effective for the transport 
of peptides and other agents through the BBB (Kreuter et al., 2003; Nahar et al., 2006). The 
use of biodegradable polymers favors the sustained release of drugs / genes into the target 
site over a long period  (Tang et al., 2009). 
Dendrimers are highly branched three-dimensional macromolecules surrounding a central 
core, which can be designed at the nanoscale with remarkable precision. Dendrimers have a 
number of free ends, to which molecules of different nature, from therapeutic agents to 
fluorescent molecules can be attached and transported. Different drugs or DNA molecules 
can be incorporated at the core, and because of its branched structure, a single dendrimer 
can carry a high number of molecules compared to other transport systems based on 
nanoparticles. Multiple terminal groups which are predominantly located on the surface 
may control the interaction of the macromolecules of dendrimer with their molecular 
environment. In fact, dendrimers tend to contain more than 100 end-groups, with diverse 
reactive sites to allow conjugation with different types of molecules (Jain & Gupta, 2008). 
Moreover, these end groups can be modified to make their interior hydrophilic and to keep 
their exterior hydrophobic, or vice versa (Sahoo &Labhasetwar, 2003). It has recently been 
shown that dendrimers can be promising gene transfer vectors for Parkinson's disease. 
Examples will be included later. 
Fullerenes are small spheres of a few nanometers in size (nanospheres), consisting of carbon 
atoms located in such a way as to form nanoscale hexagonal and pentagonal structures. The 
best known fullerene is the carbon 60 (C-60), which consists of 60 carbon atoms forming a 
structure similar to that of a soccer ball. A water-soluble fullerene, derived from the C-60, 
capable of crossing the cell membrane and that it mainly located in mitochondria has been 
reported (Foley et al., 2002). This opens up great possibilities for mitochondrial gene 
therapy, for example, in Parkinson's disease, bearing in mind the important role of 
mitochondria in this disorder. The carbon nanospheres derived from glucose are an 
emerging class of intracellular vectors. The surfaces of these spheres are highly 
functionalized and require no further modification. The in vivo experiments have shown that 
these nanospheres can cross the BBB and are identified in the brain as well as in the liver 
and spleen (Selvi et al., 2008; Wong-Ekkabut et al., 2008). There is also evidence that 
nanospheres are continually being removed from these tissues over time. 
Although non-viral vectors based on nanoparticles are easily produced and have low 
immunogenicity, there are issues about toxicity, specificity, regulation of transgene 
expression and transfection efficiency which need to be resolved before clinical application. 
7. Application of nanoparticles in gene therapy for Parkinson’s disease 
The preferred strategy, in gene therapy of diseases affecting large areas of the brain, would 
be to administer vectors systemically. The human brain contains around 100 million 
capillaries covering a surface of approximately 12 m2 (Bickel et al., 2001). Virtually every 
neuron in the brain has its own capillary, with an average distance of capillary to neuron of 
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8-20 microns (Schlageter et al., 1999). The administration of a therapeutic gene to neurons 
through the capillary membrane would then be the method of choice. However, we have 
previously seen that the BBB is a serious obstacle to the entry of macromolecules in the 
brain. 
The basic mechanism, coined by Pardridge as molecular Trojan horses, is that a protein or 
DNA that is going to cross the BBB is coupled /conjugated to a ligand that is recognized by 
a receptor which is present on the luminal side of capillary endothelial cells of the brain. 
Once in the blood, the complex protein / DNA-ligand bind to the receptor, performing a 
process of endocytosis. This complex then moves through the endothelial cytoplasm, 
thereby avoiding the endosomal / lysosomal system, where it is then left on the abluminal 
side (brain). This system of transporting proteins across the BBB has been successfully used 
for vasoactive intestinal peptide, BDNF, epidermal growth factor, but also as pegylated 
immunoliposomes (ILP) containing plasmid DNA expressing ǃ-galactosidase, tyrosine 
hydroxylase and GDNF , among others (Zhang &Pardridge, 2009). 
We have previously mentioned that the BBB has specific receptor-mediated transport 
mechanisms, which can be used as a transport pathway of drugs/genes to the brain. The 
transferrin receptor is particularly interesting because its expression is restricted to the brain 
capillaries and to neuronal membranes (Jefferies et al, 1984). ILP have been used to deliver 
genes for the targeting of the brain with colloidal carriers. The transfer of pegylated 
immunoliposomes from the blood to the brain is achieved by monoclonal antibodies 
targeted against the transferrin receptor or insulin, which, by binding to their respective 
ligands induce receptor-mediated endocytosis (transcytosis), then subsequently incorporate 
foreign genes into the brain parenchyma without damaging the BBB. The gene for tyrosine 
hydroxylase (TH) has been expressed with intravenous administration of pegylated 
immunoliposomes in a PD model with 6-hydroxydopamine, which revealed the 
normalization of expression levels of TH in the striatum (Zhang et al., 2003). 
Compared with liposomes, pegylated nanoparticles are physically and chemically more 
stable and can be lyophilized for long term storage. The pegylated nanoparticles conjugated 
with cationic albumin (CBSA-NP) may also be used for the transfer of genes to the brain (Lu 
et al., 2005). Therefore, more CBSA-NP marked with a fluorescent probe are accumulated in 
mouse brain cells (after being injected intravenously) than when using pegylated 
nanoparticles conjugated with native albumin. CBSA-NP incorporating plasmid expressing 
cytotoxic genes have been used for non-invasive experimental gene therapy of gliomas (Lu 
et al., 2006). Thus, for the first time, the transfer of a cytotoxic gene using a noninvasive 
route in the mouse brain to treat a malignant glioma has been demonstrated. The current 
findings encourage further studies into the application of CBSA-NP for noninvasive gene 
therapy of PD. 
Polyamidoamine dendrimers (PAMAM) have recently emerged as a new class of nanoscale  
spherical polymers to have caught the eye of researchers from various scientific disciplines. 
It is increasingly clear that PAMAM is a multifunctional polymer with many applications, 
such as transfer vehicles for antisense oligonucleotides and siRNA (Kang et al., 2005). 
Moreover, in itself, PAMAM can behave as an efficient gene carrier. PAMAM possessing 
primary amino surface groups have the inherent ability to associate with and condense 
DNA, and have been used efficiently in biocompatible DNA transfer (Kim et al., 2004). Good 
efficiency of transfection is also achieved by modifying the surface of PAMAM with L-
arginine. The primary amines located on the surface of these dendrimers allow conjugation 
with some ligands such as transferrin, to achieve efficient gene transfer to the brain. A 
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vector for gene transfer in the brain was recently developed with this in mind. Remember 
that the transferrin receptor is expressed in the BBB and the neuronal membrane (Jefferies et 
al, 1984). Intravenous injection in mice of a nanoscale highly branched dendrimer modified 
with transferrin and PEG (a hydrophilic polymer that increases the biocompatibility of the 
vector) (PAMAM-PEG-Tf), induces a higher brain expression (almost double compared to 
other dendrimeric vectors) of an exogenous gene encapsulated in the vector (Huang et al., 
2007a). 
Intravenous administration of PAMAM dendrimers conjugated to lactoferrin (Lf) using 
bifunctional PEG allows the efficient expression of exogenous genes in the brain. As a ligand 
targeting the brain, the Lf can bind specifically with Lf receptors of brain cells. The Lf is an 
iron-binding glycoprotein belonging to the transferrin family. One of the advantages of Lf as 
a ligand for gene therapy in brain is the low plasma concentration of endogenous Lf (5 nM). 
Its plasma concentration is much lower than the kd of Lf receptors in the BBB (Huang et al., 
2007b). This efficiently prevents the competitive inhibition of endogenous Lf with 
exogenously transference systems of genes/drugs cojugated to Lf. In addition, Lf transport 
across the BBB monolayer model appears to be unidirectional i.e. from apical to basolateral 
side. This unidirectional transport could result in a greater neuronal accumulation of such 
systems of Lf conjugates when compared to conjugates of transferrin. These advantages are 
partially reflected in a recent study showing that exogenous gene expression in the brain, 
mediated by nanoparticles conjugated to Lf is almost 5.2 times that obtained with 
unconjugated nanoparticles (Huang et al., 2008). In vivo image analysis has shown that Lf-
nanoparticles accumulation was higher in the brain (but lower in other organs) than their 
unmodified counterparts (Huang et al., 2010a). A recent study has reported significant 
neuroprotective effects with Lf-nanoparticles carrying the GDNF gene, after being 
administered intravenously in a rat model of PD induced by the pesticide substance 
rotenone (Huang et al., 2010b). 
However, the application of different transfer protocols has been limited by the lifetime of 
the protein in circulation, the need for repeated injections or low transference yields 
achieved in the brain. The recently published paper by Spencer and Verma gives a possible 
solution to the first two issues (Spencer & Verma, 2007). 
The low-density lipoprotein (LDL) receptor (LDLR) family consists of a cell-surface 
receptors group that binds lipoprotein complexes for internalization to the lysosomes. This 
family consists of about 10 different receptors that are expressed in a tissue-specific manner 
and primarily bind apolipoprotein complexes (Brown & Goldstein, 1986). The 
apolipoproteins, whose more representative members are apolipoprotein B and 
apolipoprotein E, are attached to blood lipids in order to direct them to lysosomal 
degradation. Apolipoproteins bind to the LDLR on the cell surface of the targeted cell, and 
thereby the complex is endocytosed. In contrast, when LDLR binds to apolipoproteins in 
BBB it induces transcytosis to the abluminal side of the BBB and, presumably, the 
apolipoprotein is released and taken up by neurons and/or astrocytes (Hussain et al., 1999).  
Spencer and Verma used a lentivirus vector system to deliver the lysosomal enzyme 
glucocerebrosidase and a secreted form of GFP to the neurons and astrocytes in the CNS. 
These authors fused the LDLR-binding domain of the apolipoprotein B to the targeted 
protein, moreover adding a secretory leader sequence to allow its release. It took a single 
intraperitoneal injection of lentiviral vector for the protein could be detected two weeks later 
in the CNS, showing that it had entered through transcytosis by binding to the LDLR 
(Spencer & Verma, 2007). 
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The interesting thing about this therapeutic approach is that the lentiviral vector can also 
deliver genes to a peripheral organ (liver or spleen), which now serve as a source for the 
prolonged and continuous expression, and secretion of a therapeutic protein which has the 
ability to cross the BBB. This technique could be used to facilitate the passage of 
neuroprotective molecules, of interest in Parkinson's disease, through BBB. But there are still 
some unresolved issues, for example, the immunogenicity of the fusion protein and the 
restricted cerebral distribution of LDLR, as only a minority of brain cells are transfected. The 
first problem will be difficult to address while the latter may possibly be solved using other 
receptors that activate transcytosis, such as the diphtheria toxin receptor (De Boer & 
Gaillard, 2007). 
8. Towards a non invasive gene therapy for Parkinson’s Disease 
Direct administration of transgenes in neural tissue (iGT) has advantages for the treatment 
of certain neurological diseases because it avoids the peripheral expression of the transgene 
(and related immune activation), and widespread central expression (unnecessary in focal 
neurological diseases). However, iGT also has significant drawbacks, most notably the use 
of surgical procedures (with BBB damage, nonspecific reactive gliosis, risk of infection ...) 
that cannot be repeated many times in the case of chronic diseases. In addition, this mode of 
administration usually induces intense effects on the injected brain regions, but does not 
diffuse well in the surrounding tissue (exponential decrease of transgene expression with 
distance from the injection point), and making it difficult to adjust the therapeutic dose. In 
contrast, non-invasive gene therapy (niGT) allows greater distribution of the transgene in 
the brain (particularly useful in diseases with diffuse brain affectation) and does not require 
surgery, thus allowing repeated administration in chronic neurological diseases (the most 
enduring expression of the transgene has been reported for AAV and has always been less 
than 10-15 months). 
All gene therapy clinical trials for the treatment of PD have used the iGT, which makes 
sense when the therapeutic objective is aimed at preventing the degeneration of 
dopaminergic neurons or treating the primary symptoms associated with a specific motor 
area. However, it is becoming increasingly clear that from its initial stage, PD does affect 
non dopaminergic neuronal populations of different brain centres (brain cortex, olfactory 
bulb, pedunculopontine nucleus, locus coeruleus ...), inducing symptoms that go far beyond 
the original motor disorders associated with dopaminergic transmission (autonomic 
disorders, dementia, attentional disorders, sleep disorders, depression ...). For example, 
the anatomical substrate of depression has been associated with changes in either 
noradrenaline, serotonin and dopamine transmission in various centers such as the locus 
coeruleus, raphe nuclei, or various centers of the basal ganglia and the limbic system 
(Levy & Dubois, 2006; Remy et al., 2005). While in PD without dementia, cognitive 
impairments are associated with abnormalities in dopamine transmission in the cerebral 
cortex and ventral striatum (Owen et al., 1995), PD with dementia also includes disorders 
in cortical cholinergic transmission (Klein et al., 2010). Therefore, future gene therapy for 
this disease should target not only the dopamine centres associated with motor disorders, 
but also other centres and other neurotransmitters. From this perspective, the greatest 
extension of the effects of niGT (compared with iGT) might be particularly useful in 
patients with widespread central affectation; such therapeutic actions would be difficult 
to achieve using iGT. 
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9. Towards a regulatable gene therapy for Parkinson’s Disease 
All current gene therapy approaches for Parkinson’s disease use non-adjustable constituent 
vectors, so that in all cases the transgene expression, once introduced in the body, escapes 
any external-non-adjustable gene therapy (nrGT). It is often true that animal studies show 
that therapeutic responses induced by nrGT are achieved with significantly lower doses 
than  those capable of inducing undesirable side effects. In fact, in the three annotated gene 
therapies for PD, the dose which is intended to produce therapeutic responses is 
significantly lower than that for which undesirable side effects would be expected, 
suggesting an acceptable safety profile even when using non adjustable constituent vectors 
(although the available evidence in humans comes from only relatively small samples of 
patients who have only been followed for short periods after treatment).  
Bearing in mind these considerations and taking into account the extensive AAV2 
information evidencing either its low toxicity, lack of regulated promoters shown to be safe 
and effective in patients, and urgent clinical need in numerous neurological diseases 
(particularly PD), some authors have suggested that the use of adjustable vectors for human 
gene therapy is unnecessary and could even be inappropriate and potentially dangerous 
(Kordower & Olanow, 2008). Other authors, however, defend the need for regulatable 
promoters whenever possible, because they allow continuous monitoring of transgene 
expression and impede the occurrence of incidents (Cress, 2008). There is little information 
on the effects of sustained overexpression (months to years) or nonspecific (neurons and 
glia) of particular genes, which is especially relevant in the case of proteins such as 
neurotrophic factors whose receptors are widely distributed throughout the CNS. Therefore, 
it is foreseeable that in the coming years gene therapy clinical trials will start using 
regulatable gene therapy (rGT) with regulatable vectors (Cress, 2008), which would adjust 
transgene expression to its maximum biological efficiency with minimum risk of adverse 
effects.  
Transgene expression is coupled to a transcriptional switch in the regulatable vectors 
(instead of being under the control of a constitutive promoter) whose activity can be 
regulated by an exogenous chemical. Several regulatable promoter systems by agents such 
as tetracycline (tet), rapamycin, mifepristone and ecdysone have been tested in animals. The 
best known regulatory systems are tet systems, which have shown to be efficient and safe in 
controlling the expression of transgenes in experimental models of various neurological 
diseases (Régulier et al., 2003; Blesch et al., 2005; Nuber et al., 2008). Tet systems have been 
developed that can promote activation (tet-ON) or inactivation (tet-OFF) of gene expression, 
systems that have been incorporated in lentivirus, adeno-associated virus, first-generation 
adenovirus or high capacity, and retrovirus. The tet system choice depends on the timing of 
transgene activation which is preferable in each case. It is better to use tet-off for a sustained 
expression of the transgene, while the tet-ON might be more suitable for transgene 
expression in shorter time windows, which would minimize the time of exposure of patients 
to chemicals not without toxicity.  
Besides being a safety mechanism against uncontrolled overexpression, regulation of 
transgene activity could allow flexibility in the control of the therapeutic response, which is 
difficult to achieve by other methods. The patients' clinical conditions usually change over 
the course of the disease (Collier et al., 2007); thereby adjusting the dose of rGT could be key 
to its long-term usefulness. Since the degree of injury is specific for each patient, the 
response to gene therapy may vary considerably among different patients, so the inclusion 
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of a failsafe mechanism (in this case of a regulatable vector) could be critical for the 
treatment of some patients. Neurodegenerative diseases, with the development of 
biomarkers, could begin to be treated before the onset of symptoms. A regulated system 
would enable the development of a single gene construct, whose expression could be 
adjusted to the changing needs of each patient. In addition, advanced systems are being 
developed that allow the regulation of multiple transgenes introduced into the same vector 
and are independently controlled by different inducers (Kumar et al., 2004; Goverdhana et 
al., 2005). This could lead to the development of a complex rGT, in which multiple 
transgenes (eg, for several neurotrophic factors) may act synergistically on different 
therapeutic targets. 
Despite the many potential benefits of rGT, its clinical use requires further detailed basic 
studies. There are challenges to be resolved before rGT can be considered as a safe and 
efficient therapeutic tool. This is the case of regulatable transgene expression inhibition in 
off (as tet-OFF), which may have toxic effects even at low sustained expression.  The 
penetration would also have to be optimized in terms of the modulating agent in the target 
tissue /organ. Finally, more studies are needed to determine whether the immune system 
can recognize components of the system for regulating transgene expression, which may be 
particularly relevant in cases in which, as with tet-ON, the expression must be maintained 
for long periods (as would be the case in the treatment of chronic neurological diseases.) 
10. Conclusions 
Gene therapy is considered to be one of the most promising approaches to develop an 
effective treatment for PD, and clinical studies using such technology have progressed 
rapidly in less than a decade. However, the existence of BBB significantly limits its 
development, so all gene therapy clinical trials for the treatment of PD have used iGT, which 
has significant drawbacks. It is becoming increasingly clear that from its initial stage, PD 
does affect non dopaminergic neuronal populations of different brain centres, inducing 
symptoms that go far beyond the original motor disorders associated with dopaminergic 
transmission.  
The development of new serotypes of adenoassociated vectors, such as AAV9, and of 
functionalized nanoparticles, such as pegylated immunoliposomes, polymeric nanoparticles, 
pegylated nanoparticles, dendrimers, fullerenes, as well as specific transporters specific to 
the low density lipoprotein receptor family, means that it is now possible to introduce and 
express gene material in nerve tissue following peripherical administration of the above 
mentioned vectors (niGT). From this perspective, the greatest extension of the effects of 
niGT might be particularly useful in patients with widespread central affectation, such 
therapeutic actions are difficult to achieve with iGT. Current gene therapy approaches for 
PD use non-adjustable constituent vectors, so that in all cases the transgene expression, once 
introduced it in the body, escapes any external-non-adjustable gene therapy. Therefore, it is 
foreseeable that in coming years gene therapy clinical trials for PD will start to use 
regulatable gene therapy (rGT) which would adjust transgene expression to its maximum 
biological efficiency with minimum risk of adverse effects.  
Having crossed the Rubicon, one can then expect the following challenges, for example, to 
produce efficient vectors with regulatable promoters, to reduce the transduction of 
peripheral organs, to target vectors to specific neuronal and glial populations, and to 
demonstrate the reversal of the disease in animal models of PD. The administration of 
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therapeutic drugs to treat CNS disorders is a common problem shared by pharmacologists 
and gene therapists, but the field of noninvasive gene transfer in the CNS is on the verge of 
an exciting step forward. Animal studies are highly promising and it is likely that, in the 
future, gene therapy procedures will be useful and safe for use in patients. 
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